Lava Therapeutics logo

Initial Public Offering on Nasdaq

USD 101 million
Lead Manager
;

LAVA Therapeutics

Kempen & Co acted as Lead Manager in LAVA Therapeutics’ Initial Public Offering on Nasdaq

Transaction highlights

  • LAVA Therapeutics raised USD 101 million in its Initial Public Offering on Nasdaq
  • A total of 6,700,000 common shares were offered at an offer price of USD 15.00 per share (excluding the underwriters’ 30-day option to purchase up to an additional 1,005,000 common shares at the initial public offering price) 
  • Proceeds of this transaction will be used to advance lead program LAVA-051 for the treatment of multiple myeloma, chronic lymphocytic leukaemia, and acute myeloid leukaemia and to advance the development of LAVA 206x207 for the treatment of metastatic castrate-resistant prostate cancer
  • We take great pride in having supported LAVA Therapeutics in their US Nasdaq IPO trajectory which marks the 11th life sciences & healthcare equity capital markets transaction by Kempen & Co year-to-date 

Company description

LAVA Therapeutics is a Dutch biotech company focusing on gamma-delta t cell engagers to transform cancer therapy. Their platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 T cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Their lead program, LAVA-051, targets the tumour specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukaemia, and acute myeloid leukaemia, among other tumour types. 

Background Kempen & Co Life Sciences & Healthcare

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

  • Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering of European Biotech Acquisition Corp (EBAC)
  • Joint Bookrunner in the SEK 1.1 billion capital increase by Oncopeptides
  • Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
  • Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
  • Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
  • Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
  • Bookrunner in the USD 518 million US Public Offering by CureVac
  • Lead Manager in the USD 120 million US Public Offering by Merus 
  • Financial Adviser to DCprime in its merger with Immunicum 
  • Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
  • Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
  • Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
  • Lead Manager in the USD 95.1 million Nasdaq Initial Public Offering by Galecto
  • Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
  • Bookrunner in the USD 245 million Nasdaq Initial Public Offering by Curevac
  • Co-Manager in the USD 49.0 million US Public Offering by Centogene
  • Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
  • Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
  • Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
  • Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp, thereby becoming a Nasdaq listed company and securing USD 253 million
  • Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
  • Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
  • Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
  • Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
  • Co-Manager in the USD 862 million Global Offering by Argenx
  • Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides

Contact

Nadine Maalouf
Kathrin Erfurth

Transactions